Maxigen Biotech Inc. (TPE:1783)
Taiwan
· Delayed Price · Currency is TWD 44.00
+0.20 (0.46%)
Jul 9, 2025, 1:30 PM CST
Maxigen Biotech Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Net Income | 208.84 | 190.17 | 165.83 | 139.4 | 87.67 | 63.31 | Upgrade
|
Depreciation & Amortization | 27.5 | 26.85 | 27.24 | 29.05 | 32.31 | 32.75 | Upgrade
|
Other Amortization | 0.12 | 0.18 | 0.37 | 0.53 | 0.59 | 0.44 | Upgrade
|
Loss (Gain) From Sale of Assets | - | 0 | -13.62 | -1.03 | - | - | Upgrade
|
Stock-Based Compensation | 5.68 | 6.69 | 7.69 | 13.48 | 2.45 | - | Upgrade
|
Provision & Write-off of Bad Debts | 14.47 | 14.47 | 0.2 | 4.72 | 3.02 | -0.1 | Upgrade
|
Other Operating Activities | 6.73 | 4.78 | -5.4 | 15.37 | 1.28 | -11.69 | Upgrade
|
Change in Accounts Receivable | -21.51 | -29.78 | -3.8 | -12.26 | -6 | 14.08 | Upgrade
|
Change in Inventory | 4.03 | 9.45 | -9.91 | 3.68 | 8.03 | 1.13 | Upgrade
|
Change in Accounts Payable | 47.15 | 32.87 | -18.82 | -4.11 | 7.05 | -0.92 | Upgrade
|
Change in Unearned Revenue | 1.26 | 21.6 | -2.92 | -6.88 | 7.36 | -3.96 | Upgrade
|
Change in Other Net Operating Assets | 24.24 | 20.96 | 24.33 | 86.38 | -26.18 | -20.49 | Upgrade
|
Operating Cash Flow | 318.52 | 298.22 | 171.2 | 268.34 | 117.59 | 74.56 | Upgrade
|
Operating Cash Flow Growth | 58.55% | 74.20% | -36.20% | 128.19% | 57.71% | -21.03% | Upgrade
|
Capital Expenditures | -31.07 | -31.77 | -22.44 | -14.29 | -14.26 | -10.74 | Upgrade
|
Sale of Property, Plant & Equipment | - | - | 0.9 | 6.28 | - | - | Upgrade
|
Sale (Purchase) of Intangibles | - | - | - | -0.15 | -1.19 | -0.6 | Upgrade
|
Investment in Securities | - | - | -491.27 | 16.56 | -13.74 | 151.92 | Upgrade
|
Other Investing Activities | -7.88 | 2.7 | -0.03 | 2.04 | 26.41 | -1.62 | Upgrade
|
Investing Cash Flow | -38.95 | -29.07 | -490.25 | 10.43 | -2.78 | 138.96 | Upgrade
|
Long-Term Debt Repaid | - | - | - | -0.95 | -2.49 | -2.56 | Upgrade
|
Net Debt Issued (Repaid) | - | - | - | -0.95 | -2.49 | -2.56 | Upgrade
|
Issuance of Common Stock | 24.03 | 28.69 | 0.96 | - | 247.35 | - | Upgrade
|
Common Dividends Paid | -88.96 | -88.96 | -42.35 | - | -56.27 | -54.18 | Upgrade
|
Dividends Paid | -88.96 | -88.96 | -42.35 | - | -56.27 | -54.18 | Upgrade
|
Other Financing Activities | 7.4 | 0.54 | - | -0.1 | 0.1 | -0.07 | Upgrade
|
Financing Cash Flow | -57.53 | -59.73 | -41.39 | -1.05 | 188.69 | -271.35 | Upgrade
|
Foreign Exchange Rate Adjustments | -2.3 | -1.45 | 0.57 | -0.08 | 0.03 | -0.06 | Upgrade
|
Net Cash Flow | 219.74 | 207.97 | -359.87 | 277.64 | 303.54 | -57.88 | Upgrade
|
Free Cash Flow | 287.45 | 266.45 | 148.76 | 254.05 | 103.34 | 63.82 | Upgrade
|
Free Cash Flow Growth | 61.52% | 79.12% | -41.44% | 145.85% | 61.91% | -10.54% | Upgrade
|
Free Cash Flow Margin | 39.34% | 39.15% | 23.91% | 42.03% | 20.18% | 13.94% | Upgrade
|
Free Cash Flow Per Share | 3.19 | 2.97 | 1.66 | 2.84 | 1.22 | 0.79 | Upgrade
|
Cash Interest Paid | - | - | - | 0.07 | 0.2 | 8.83 | Upgrade
|
Cash Income Tax Paid | 30.51 | 30.6 | 32.72 | 10.76 | 8.52 | 16.6 | Upgrade
|
Levered Free Cash Flow | 202.04 | 186.08 | 91.4 | 209.69 | 71.5 | 37.21 | Upgrade
|
Unlevered Free Cash Flow | 202.04 | 186.08 | 91.4 | 209.73 | 71.62 | 37.36 | Upgrade
|
Change in Net Working Capital | -70.68 | -71.7 | 15.13 | -100.72 | 4.5 | 22.68 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.